March 31, 2025

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer – Business Wire

March 31, 2025

FDA Approves Durvalumab (Imfinzi) for Muscle-Invasive Bladder Cancer – Oncology News Central

March 31, 2025

FDA approves AstraZeneca’s IMFINZI for bladder cancer By Investing.com – Investing.com UK

March 31, 2025

Evolving Treatment Landscape for Non-Muscle Invasive Bladder Cancer Beyond BCG – Bogdana Schmidt – UroToday

March 31, 2025

Imfinzi by AstraZeneca gets US approval for bladder cancer treatment – Investing.com Canada